A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation

NCT02241460 Phase 3 UNKNOWN

The purpose of this study is to evaluate the efficacy of treatment with Promescent Lidocaine Spray compared with placebo in patients with premature ejaculation.

Details

Lead sponsor	Eugene Y Rhee, MD
Phase	Phase 3
Status	UNKNOWN
Enrolment	120
Start date	2014-03
Completion	2015-12

Conditions

• Premature Ejaculation

Interventions

• Placebo
• Promescent Lidocaine Spray

Primary outcomes

• Intravaginal Ejaculatory Latency Time (IELT) in seconds — Week 11
  The primary efficacy outcome is the proportion of subjects that achieve a mean IELT of greater than 90 seconds at Week 3, 7, and 11.

Countries

United States